Integrated analysis of genomic and epigenomic alterations in circulating tumor DNA in patients with biliary tract cancer
- Conditions
- Biliary tract cancer
- Registration Number
- JPRN-UMIN000052780
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 110
Not provided
1.History of malignancy with a disease-free period of 5 years or less. *1 2.Clinically suspected coexistence of cancer of other organs. 3.Women who are pregnant or intend to become pregnant. 4.Judged by physician to be unsuitable for enrolment in the study. *1Pre-existing cancer with a disease-free interval of less than 5 years, but with a 5-year relative survival equivalent to 95% or more, such as stage I prostate cancer, stage 0 or stage I laryngeal cancer with a complete response to radiotherapy, or cancer of the following pathological stages that has been completely resected, will not be excluded and will be eligible for enrolment. Gastric cancer (adenocarcinoma [general type]): Stage 0 - Stage I Colorectal cancer (adenocarcinoma): Stage 0 - Stage I Esophageal cancer (flat epithelial carcinoma, adeno flat epithelial carcinoma, basaloid carcinoma): Stage 0 Breast cancer (non-invasive ductal carcinoma, non-invasive lobular carcinoma): stage 0 Breast cancer (invasive ductal carcinoma, invasive lobular carcinoma, Paget's disease): stage 0-IIA Uterine body cancer (endometrioid adenocarcinoma, mucinous adenocarcinoma): stage IA Anterior adenocarcinoma (adenocarcinoma): Stage I - IIA Cervical Cancer (Flat Epithelial Carcinoma): Stage IA Thyroid Cancer (Breast Cancer, Follicular Cancer): Stage I, II, III Kidney Cancer (Haplocellular Carcinoma, Haplocellular Carcinoma): Stage I Other Intramucosal Cancer Comparable Transformation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive rates of GUARDANT assays in resectable biliary tract cancer
- Secondary Outcome Measures
Name Time Method